Ribonucleic Acid Interference (RNAi) Medicine Market Report 2026
Global Outlook – By Type (Small Interfering Ribonucleic Acid, Micro Ribonucleic Acid, Short Hairpin Ribonucleic Acid, Other Types), By Delivery Method (Nanoparticles, Liposomes, Viral Vectors, Other Delivery Methods), By Application (Oncology, Cardiovascular, Infectious Diseases, Genetic Disorders, Other Applications), By End User (Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End Users) – Market Size, Trends, Strategies, and Forecast to 2030
Ribonucleic Acid Interference (RNAi) Medicine Market Report 2026 Market Overview
• Ribonucleic Acid Interference (RNAi) Medicine Market Report 2026 market size has reached to $4.06 billion in 2025 • Expected to grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 17.6% • Growth Driver: Rising Personalized Medicine Adoption Fueling The Growth Of The Market Due To Increasing Genetic Testing And Genomic Sequencing Technologies • Market Trend: Stimuli-Responsive siRNA Platforms Advance Precision Gene Silencing And Targeted RNAi Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Ribonucleic Acid Interference (RNAi) Medicine Market?
The ribonucleic acid interference (RNAi) medicine is a therapeutic approach that uses small ribonucleic acid (RNA) molecules to suppress the activity of specific genes responsible for disease development. It works by targeting and degrading messenger RNA (mRNA), thereby preventing the production of harmful proteins in the body. The main types of ribonucleic acid interference (RNAi) medicine include small interfering ribonucleic acid, micro ribonucleic acid, short hairpin ribonucleic acid, and other types. Small interfering ribonucleic acid refers to short double stranded RNA molecules that silence specific genes by targeting messenger RNA for degradation. These medicines use delivery methods such as nanoparticles, liposomes, viral vectors, and other delivery methods. They find application in oncology, cardiovascular, infectious diseases, genetic disorders, and others, serving end users including pharmaceutical companies, biotechnology companies, research institutes, and others.
What Is The Ribonucleic Acid Interference (RNAi) Medicine Market Size and Share 2026?
The ribonucleic acid interference (RNai) medicine market size has grown rapidly in recent years. It will grow from $4.06 billion in 2025 to $4.79 billion in 2026 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to discovery of rna interference mechanism, early-stage clinical trial failures in oligonucleotide therapies, improvements in rna synthesis and stabilization technologies, rise of antisense oligonucleotide research, increasing funding for rare disease research initiatives.What Is The Ribonucleic Acid Interference (RNAi) Medicine Market Growth Forecast?
The ribonucleic acid interference (RNai) medicine market size is expected to see rapid growth in the next few years. It will grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expansion of regulatory approvals for rna based therapeutics, increasing pipeline of targeted gene silencing drugs, growing adoption of advanced delivery platforms improving cellular uptake, rising orphan drug incentives across global markets, reduction in manufacturing and synthesis costs of oligonucleotide therapies. Major trends in the forecast period include advancement in targeted delivery vectors for rna silencing therapeutics, expansion of long-acting and sustained release rna interference formulations, increasing focus on off-target effect reduction and safety profiling, growing adoption of combination therapies integrating rna interference with monoclonal antibodies and small molecules, expansion into rare genetic disorder treatment indications.
Global Ribonucleic Acid Interference (RNAi) Medicine Market Segmentation
1) By Type: Small Interfering Ribonucleic Acid, Micro Ribonucleic Acid, Short Hairpin Ribonucleic Acid, Other Types 2) By Delivery Method: Nanoparticles, Liposomes, Viral Vectors, Other Delivery Methods 3) By Application: Oncology, Cardiovascular, Infectious Diseases, Genetic Disorders, Other Applications 4) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End Users Subsegments: 1) By Small Interfering Ribonucleic Acid: Synthetic Small Interfering Ribonucleic Acid, Lipid Nanoparticle Small Interfering Ribonucleic Acid, Conjugated Small Interfering Ribonucleic Acid, Therapeutic Small Interfering Ribonucleic Acid, Research Grade Small Interfering Ribonucleic Acid, Targeted Delivery Small Interfering Ribonucleic Acid 2) By Micro Ribonucleic Acid: Diagnostic Micro Ribonucleic Acid, Therapeutic Micro Ribonucleic Acid, Circulating Micro Ribonucleic Acid, Biomarker Based Micro Ribonucleic Acid, Exosome Derived Micro Ribonucleic Acid, Cancer Associated Micro Ribonucleic Acid 3) By Short Hairpin Ribonucleic Acid: Vector Based Short Hairpin Ribonucleic Acid, Viral Delivered Short Hairpin Ribonucleic Acid, Stable Expression Short Hairpin Ribonucleic Acid, Inducible Short Hairpin Ribonucleic Acid, Gene Silencing Short Hairpin Ribonucleic Acid, Research Application Short Hairpin Ribonucleic Acid 4) By Other Types: Antisense Oligonucleotide Therapies, Circular Ribonucleic Acid Therapeutics, Aptamer Based Therapeutics, Ribonucleic Acid Nanoparticle Therapeutics, Self Amplifying Ribonucleic Acid Therapeutics, Messenger Ribonucleic Acid Interference TherapeuticsWhat Is The Driver Of The Ribonucleic Acid Interference (RNAi) Medicine Market?
The rising personalized medicine adoption is expected to propel the growth of the RNAi medicine market going forward. Personalized medicine is a medical approach that tailors disease prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and biological characteristics. Personalized medicine is increasing due to the growing adoption of genetic testing and genomic sequencing technologies, which enable healthcare providers to identify individual genetic variations and deliver more precise and targeted treatments that improve patient outcomes. RNAi medicine helps personalized medicine by enabling targeted gene silencing based on a patient’s specific genetic profile and disease mechanism, supporting the development of precise therapies that improve treatment effectiveness while minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rising personalized medicine adoption is driving the growth of the RNAi medicine market.Key Players In The Global Ribonucleic Acid Interference (RNAi) Medicine Market
Major companies operating in the ribonucleic acid interference (rnai) medicine market report are F. Hoffmann-La Roche Ltd., Novartis AG, Novo Nordisk A/S, Sirius Therapeutics Inc., Alnylam Pharmaceuticals Inc., Switch Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Silence Therapeutics plc, Vir Biotechnology Inc., Arbutus Biopharma Corporation, City Therapeutics Inc., ADARx Pharmaceuticals Inc., Comanche Biopharma Corp., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Nitto BioPharma Inc., Benitec Biopharma Inc., Phio Pharmaceuticals Corp., Ionis Pharmaceuticals, Sarepta Therapeutics, Regeneron Pharmaceuticals, Sanofi, GSK plc
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Ribonucleic Acid Interference (RNAi) Medicine Market Trends and Insights
Major companies operating in the RNAi medicine market are focusing on developing technological advancements, such as stimuli-responsive siRNA platforms, to enhance targeted gene silencing, improve therapeutic precision, and minimize off-target effects in disease treatment. Stimuli-responsive siRNA platforms are advanced RNA interference delivery systems designed to activate or release small interfering RNA (siRNA) in response to specific biological or environmental triggers, such as pH changes, enzymes, temperature, or disease-specific biomarkers. For instance, in March 2023, Switch Therapeutics Inc., a US-based biotechnology company, launched the Conditionally Activated siRNA (CASi) platform, a stimuli-responsive siRNA platform. It enhances targeted gene silencing, improves therapeutic precision, and reduces off-target effects in RNA interference (RNAi)-based therapies for central nervous system diseases. The CASi (Conditionally Activated siRNA) platform features a first-of-its-kind conditional activation mechanism that enables siRNA therapies to remain inactive until reaching specific disease-associated cellular environments.What Are Latest Mergers And Acquisitions In The Ribonucleic Acid Interference (RNAi) Medicine Market?
In September 2025, Novartis AG, a Switzerland-based pharmaceutical company, partnered with Shanghai Argo Biopharmaceutical Co., Ltd. to develop and commercialize RNA interference therapeutics targeting cardiometabolic diseases. With this partnership, companies aimed to combine Novartis’ global drug development and commercialization expertise with Argo’s RNAi platform technologies to accelerate the development of innovative RNAi-based medicines and expand therapeutic options for patients with chronic cardiometabolic disorders. Shanghai Argo Biopharmaceutical Co., Ltd. is a China-based biotechnology company focused on developing RNA interference therapeutics and gene-silencing technologies for cardiovascular, metabolic, and other chronic diseases.
Regional Outlook
North America was the largest region in the ribonucleic acid interference (RNAi) medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Ribonucleic Acid Interference (RNAi) Medicine Market?
The ribonucleic acid interference (RNAi) medicine market consists of sales of antisense oligonucleotides, dicer-substrate RNA, piwi-interacting RNA, and aptamer-RNA conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Ribonucleic Acid Interference (RNAi) Medicine Market Report 2026?
The ribonucleic acid interference (rnai) medicine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid interference (rnai) medicine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Ribonucleic Acid Interference (RNAi) Medicine Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $4.79 billion |
| Revenue Forecast In 2030 | $9.17 billion |
| Growth Rate | CAGR of 17.6% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Delivery Method, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd., Novartis AG, Novo Nordisk A/S, Sirius Therapeutics Inc., Alnylam Pharmaceuticals Inc., Switch Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Silence Therapeutics plc, Vir Biotechnology Inc., Arbutus Biopharma Corporation, City Therapeutics Inc., ADARx Pharmaceuticals Inc., Comanche Biopharma Corp., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Nitto BioPharma Inc., Benitec Biopharma Inc., Phio Pharmaceuticals Corp., Ionis Pharmaceuticals, Sarepta Therapeutics, Regeneron Pharmaceuticals, Sanofi, GSK plc |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |